You are viewing: Middle East Plasma Fractionation Market analysis
Part of: Plasma Fractionation Market (Global)

The Middle East Plasma Fractionation Market was valued at $797.7 Million in 2026 and projected to reach to $988.6 Million by 2031, representing a compound annual growth rate of CAGR 4.4%. The Middle East plasma fractionation market is positioned for moderate but consistent growth through 2031, supported by rising chronic disease burden, improved healthcare access, and increasing awareness of plasma-derived therapies.

Middle East Plasma Fractionation Market (2026-2031) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Middle East Plasma Fractionation Market Trends and Insights

  • The Middle East region is experiencing steady demand for plasma-derived therapies driven by increasing prevalence of bleeding disorders, immunodeficiencies, and chronic diseases.
  • The Middle East's healthcare infrastructure investments and rising awareness of plasma fractionation products are supporting market expansion during the 2026-2031 forecast period. The Middle East market benefits from growing government healthcare initiatives and private sector participation in blood collection and plasma processing.
  • The Middle East region faces challenges including regulatory complexities and limited domestic plasma collection capacity, which drive reliance on imported plasma products.
  • Despite these constraints, the Middle East plasma fractionation market is positioned for moderate growth as healthcare systems modernize and patient access to life-saving therapies improves across the region..

Key Market Statistics

  • CAGR (2026-2031) CAGR 4.4%
  • Market Size, 2026 ~USD 797.7 Million
  • Forecast, 2031 ~USD 988.6 Million
  • Geography Middle East

Middle East Plasma Fractionation Market Overview

Steady Regional Growth :

The Middle East plasma fractionation market is expanding at a CAGR of 4.4%, reaching USD 988.6 million by 2031 from USD 797.7 million in 2026, driven by increasing healthcare investments and disease prevalence.

Rising Bleeding Disorder Prevalence :

Growing incidence of hemophilia, von Willebrand disease, and other coagulation disorders across the Middle East is fueling demand for plasma-derived clotting factor therapies and immunoglobulin products.

Immunodeficiency Treatment Demand :

Increasing diagnosis and treatment of primary and secondary immunodeficiencies in the Middle East is driving adoption of intravenous immunoglobulin (IVIG) and subcutaneous immunoglobulin (SCIg) therapies.

Healthcare Infrastructure Expansion :

Enhanced healthcare facilities, improved diagnostic capabilities, and government healthcare initiatives across GCC countries and Egypt are supporting market growth and patient access to plasma therapies.

Middle East Plasma Fractionation Market Dynamics

  • Key drivers include expanding treatment protocols for bleeding disorders and immunodeficiencies, coupled with government healthcare modernization efforts in Saudi Arabia, UAE, and Egypt. Market expansion will be facilitated by growing plasma collection infrastructure, regulatory harmonization efforts, and partnerships between regional healthcare providers and international plasma manufacturers.
  • However, challenges such as high treatment costs, limited domestic plasma supply, and regulatory complexities may moderate growth rates compared to global markets, positioning the region as a steady, emerging opportunity for plasma fractionation stakeholders..

Market Ecosystem

logo-mobile

PLASMA FRACTIONATION MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES

COMPANY USE CASE DESCRIPTION BENEFITS
company logo
Implemented the Horizon 2 plasma fractionation process at its Kankakee facility to improve immunoglobulin recovery from donated plasma Higher immunoglobulin yield | Improved plasma utilization | Greater production efficiency | Increased supply capacity
company logo
Implemented process improvements through its One Day Batch Release program at plasma-derived therapy manufacturing sites to accelerate batch release Faster batch release | Improved manufacturing efficiency | Shorter lead times | Faster product availability

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

Related Ecosystem

Biotechnology

Top Technologies
  • Reagents
  • Polymerase Chain Reaction (PCR)
  • Stem Cells
  • Assay Kits
  • Flow Cytometers
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.

    Pharmaceuticals

    Top Technologies
    • Bioreactors
    • Analytical Testing
    • Bioanalytical Testing Services
    • Cell Counters
    • Data Management Services
    Top Companies
    • Thermo Fisher Scientific Inc.
    • Merck KGaA
    • SANOFI
    • Pfizer Inc.
    • NOVARTIS

      Key Takeaways

      • The Middle East plasma fractionation market is valued at USD 797.7 million in 2026 and will reach USD 988.6 million by 2031.
      • The Middle East market is growing at a CAGR of 4.4%, reflecting steady but moderate expansion compared to global growth rates.
      • The Middle East region relies heavily on imported plasma products due to limited domestic collection infrastructure and regulatory barriers.
      • The Middle East healthcare sector's modernization and increased government investment are key drivers of plasma fractionation market growth through 2031.

      Plasma Fractionation Market Report Scope

      Report Metric Details
      Base Year 2026
      Fastest Growing Segment SCIG (Type)
      Forecast Period 2026-2030
      Growth Rate CAGR of 7.6% from 2026 to 2030
      Largest Segment THERAPEUTICS (Application)
      Market Size Base Year (Billions) ~USD 36.46 (2026)
      Revenue Forecast (Billions) ~USD 48.87 (2030)
      Segments Covered Product, Type, Application, Therapeutic Area, End User

      Middle East Plasma Fractionation Market Report Segmentation

      5 segment dimensions are covered across the global market.

      By Product

      • Albumin
      • Coagulation Factor Concentrates
      • Immunoglobulins
      • Other Plasma Products
      • Protease Inhibitors

      By Type

      • Factor Ix
      • Factor Viii
      • Factor Xiii
      • Fibrinogen Concentrates
      • Ivig
      • Other Coagulation
      • Other Coagulation Factor Concentrates
      • Other Immunoglobulins
      • Prothrombin Complex Concentrates
      • Prothrombin Factor Concentrates
      • Scig
      • Von Willebrand Factor

      By Application

      • Academics & Preclinical Research
      • Therapeutics

      By Therapeutic Area

      • Critical Care
      • Hemato-Oncology
      • Hematology
      • Immunology
      • Neurology
      • Other Therapeutic Areas
      • Pulmonology
      • Rheumatology

      By End User

      • Home Care Settings & Infusion Centers
      • Hospitals & Specialty Clinics
      • Other End Users

      Target Audience

      • Plasma Fractionation Manufacturers : Global and regional plasma manufacturers need Middle East market intelligence to identify expansion opportunities, assess competitive positioning, and develop localized commercial strategies for this growing region.
      • Healthcare Providers & Hospital Networks : Hospital administrators and procurement teams require market data to optimize plasma product sourcing, negotiate supplier contracts, and plan inventory management for bleeding disorder and immunodeficiency treatments.
      • Regulatory & Government Bodies : Healthcare ministries and regulatory agencies in Middle Eastern countries use market insights to inform plasma collection policies, pricing regulations, and healthcare infrastructure investments.
      • Investment & Private Equity Firms : Investors evaluating healthcare opportunities in the Middle East need comprehensive market analysis to assess growth potential, identify acquisition targets, and evaluate risk-return profiles in plasma fractionation.
      • Distributors & Healthcare Logistics Companies : Regional distributors and supply chain partners require market forecasts and country-specific data to optimize distribution networks, manage product portfolios, and capitalize on emerging demand across GCC and non-GCC markets.

      Middle East vs. other regions

      HowMiddle East compares to the other 3 regional blocs covered in this market.

      North America
      ~USD 28658.5 Million · 7.8% wtd CAGR ·
      Europe
      ~USD 11986.7 Million · 7.3% wtd CAGR ·
      Asia Pacific
      ~USD 8714.7 Million · 8.4% wtd CAGR ·
      Latin America
      ~USD 2826.1 Million · 6.8% wtd CAGR ·

      Countries within Middle East - compare and drill down

      Country2025 size (native)
      Saudi ArabiaUSD 129.5 Million
      UAEUSD 124.7 Million
      TurkeyUSD 222.8 Million
      EgyptUSD 150.1 Million
      GCC CountriesUSD 359.8 Million
      Rest Of Middle EastUSD 255.8 Million

      Country market size visualization

      Saudi Arabia
      USD 129.5 Million
      UAE
      USD 124.7 Million
      Turkey
      USD 222.8 Million
      Egypt
      USD 150.1 Million
      GCC Countries
      USD 359.8 Million
      Rest Of Middle East
      USD 255.8 Million

      Reasons to Buy this Report

      • Regional Market Sizing & Forecasts : Obtain precise market valuations for the Middle East (USD 797.7M in 2026) with country-level breakdowns for Saudi Arabia, UAE, Egypt, and GCC nations, enabling targeted investment and expansion strategies.
      • Disease Prevalence & Treatment Insights : Understand the epidemiology of bleeding disorders and immunodeficiencies specific to Middle Eastern populations, informing product development, clinical trial design, and market entry strategies.
      • Competitive Landscape Analysis : Identify key plasma fractionation manufacturers, local distributors, and emerging players in the Middle East, along with their market positioning and growth strategies in this developing region.
      • Regulatory & Reimbursement Framework : Navigate Middle Eastern healthcare regulations, pricing policies, and reimbursement mechanisms across different countries to optimize market access and commercial viability.
      • Growth Opportunity Assessment : Leverage 4.4% CAGR projections and identify high-potential segments (immunoglobulins, clotting factors, albumin) and geographies (GCC vs. non-GCC) for resource allocation and partnership development.

      Frequently asked questions

      What is the current size of the Middle East plasma fractionation market?

      The Middle East plasma fractionation market is valued at USD 797.7 million in 2026 and is expected to grow to USD 988.6 million by 2031.

      What is the growth rate of the Middle East plasma fractionation market?

      The Middle East plasma fractionation market is growing at a CAGR of 4.4% from 2026 to 2031.

      What are the main drivers of growth in the Middle East plasma fractionation market?

      Key drivers in the Middle East include rising prevalence of bleeding disorders and immunodeficiencies, government healthcare investments, increased awareness of plasma therapies, and modernization of healthcare infrastructure.

      What challenges does the Middle East plasma fractionation market face?

      The Middle East market faces challenges including regulatory complexities, limited domestic plasma collection capacity, and dependence on imported plasma products, which can affect supply chain stability and costs.

      How does the Middle East market compare to global plasma fractionation growth?

      The Middle East's CAGR of 4.4% is lower than the global CAGR of 7.6%, indicating that the region is experiencing more moderate growth relative to worldwide market expansion.

      RESEARCH METHODOLOGY

      This research study extensively used secondary sources, directories, and databases to identify and collect valuable information for analyzing the global plasma fractionation market. In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and to assess the market's growth prospects. The global market size estimated through secondary research was triangulated with inputs from primary research to determine the final market size..

      Secondary Research

      The secondary sources for this research study include publications from government sources, such as FDA/CBER, EMA, WHO, and national health and regulatory authorities; industry associations, such as the Plasma Protein Therapeutics Association (PPTA), the International Plasma and Fractionation Association (IPFA), and AABB; and commercial databases, such as Bloomberg Business, D&B, Factiva, and relevant trade databases. Additional sources include white papers, annual reports, company house documents, investor presentations, scientific and clinical publications, regulatory filings, patent databases, and product and clinical trial databases. Secondary research was used to identify and collect information for the extensive, technical, market-oriented, and commercial study of the plasma fractionation market. It was also used to obtain important information about key players, market classification, segmentation according to industry trends, the bottom-up approach, and key developments from market and technology perspectives. Secondary data was also used to assess plasma collection capacity, fractionation and manufacturing infrastructure, product portfolios, regulatory frameworks, trade patterns, clinical applications, and regional market trends. These sources were also used to gather key information about major players, market classification, and segmentation based on industry trends, regional/country-level markets, market developments, and technological perspectives.

      Primary Research

      In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and to assess the market’s prospects. Primary sources from both the supply and demand sides of the market were interviewed to gather qualitative and quantitative information.

      Plasma Fractionation Market
 Size, and Share

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      The top-down and bottom-up approaches were used to estimate & validate the total size of the plasma fractionation market. These methods were also used extensively to estimate the size of various market segments.

      Plasma Fractionation Market : Top-Down and Bottom-Up Approach

      Plasma Fractionation Market Top Down and Bottom Up Approach

      Data Triangulation

      After evaluating the overall market size through the market size estimation process, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were used, whenever applicable, to complete the overall market engineering process and obtain precise statistics for all segments and subsegments. The data was triangulated by analyzing various factors and trends from both the demand and supply sides.

      Market Definition

      Plasma-derived therapies are medical treatments based on human plasma. Plasma is the largest component of human blood and contains water, salts, enzymes, antibodies, and other proteins. Before it can be used in medical therapies, it undergoes a fractionation process in which the relevant proteins are separated. Plasma-derived therapies are used to treat a wide range of (rare) diseases, from bleeding disorders and inhibitor deficiencies to primary and secondary immunodeficiencies.

      Key Stakeholders

      • Plasma Fractionation Product Manufacturers and Distributors
      • Pharmaceutical and Biotechnology Companies
      • Healthcare Service Providers (including Hospitals and Clinics)
      • Research and Development (R&D) companies
      • Academic Institutes
      • Government Associations
      • Market Research and Consulting Firms
      • Venture Capitalists and Investors

      Report Objectives

      • To define, describe, and forecast the plasma fractionation market based on product, application, therapeutic area, end user, and region
      • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
      • To strategically analyze micromarkets concerning individual growth trends, prospects, and contributions to the overall plasma fractionation market
      • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
      • To forecast the size of the market segments concerning six main regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
      • To strategically profile the key players in the plasma fractionation market and comprehensively analyze their core competencies and market rankings
      • To track and analyze competitive developments such as product launches, acquisitions, expansions, agreements, partnerships, and collaborations in the plasma fractionation market
      • To benchmark players within the plasma fractionation market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business and product/service strategy

      Available customizations:

      With the given market data, MarketsandMarkets offers customizations per the company’s specific needs. The following customization options are available for this report:

      Product Analysis

      • Further breakdown of the Rest of Europe Plasma Fractionation Market, by country
      • Further breakdown of the Rest of Asia Pacific Plasma Fractionation Market, by country
      • Further breakdown of the Rest of Latin America Plasma Fractionation Market, by country
      • Further breakdown of the Rest of Middle East Plasma Fractionation Market, by country

      Company Information

      • Detailed analysis and profiling of additional market players (up to five)

      Get the Full Plasma Fractionation Market Report

      Full forecast, segment splits, and company analysis for all Plasma Fractionation Market.

      Need a Tailored Report?

      Customize this report to your needs

      Get 10% FREE Customization

      Customize This Report
      Fact checked
      DMCA.com Protection Status